Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
about
Atrial fibrillation in heart failure: an innocent bystander?2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Atrial Fibrillation and Hypertension: Mechanistic, Epidemiologic, and Treatment ParallelsEffect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trialsLone atrial fibrillation: where are we now?Atrial high-rate episodes and stroke prevention.Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants.Statin Therapy for Primary Prevention of Atrial Fibrillation: Guided by CHADS2/CHA2DS2VASc Score.A meta-analysis of omega-3 fatty acids and incidence of atrial fibrillation.Reactive γ-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells.Aspirin use and risk of atrial fibrillation in the Physicians' Health Study.A new mechanism links preamyloid oligomer formation in the myocyte stress response associated with atrial fibrillation.Recent advances in the molecular pathophysiology of atrial fibrillation.Novel pharmacological targets for the rhythm control management of atrial fibrillation.TPEN prevents rapid pacing-induced calcium overload and nitration stress in HL-1 myocytes.Age and CHADS2 Score Predict the Effectiveness of Renin-Angiotensin System Blockers on Primary Prevention of Atrial FibrillationUpstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysisUpstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis.Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysisMechanisms of arrhythmias and conduction disorders in older adults.Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort StudyAtrial fibrillation in heart failure: The sword of Damocles revisited.Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsAtrial Fibrillation, Cognitive Decline And Dementia.Antioxidant therapies for the management of atrial fibrillation.Do Omega-3 Fatty Acids Decrease the Incidence of Atrial Fibrillation?Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation.Atrial fibrillation: mechanisms, therapeutics, and future directions.Cilostazol ameliorates atrial ionic remodeling in long-term rapid atrial pacing dogs.Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention.Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications.Extracellular matrix alterations in the atria: insights into the mechanisms and perpetuation of atrial fibrillation.Loss of proteostatic control as a substrate for atrial fibrillation: a novel target for upstream therapy by heat shock proteinsIndividualized therapy in patients with atrial fibrillation: new look at atrial fibrillation.Omega-3 in antiarrhythmic therapy : cons position.Clinical update on the management of atrial fibrillation.Atrial fibrillation as manifestation and consequence of underlying cardiomyopathies: from common conditions to genetic diseases.Diabetes mellitus and atrial remodeling: mechanisms and potential upstream therapies.
P2860
Q27010588-8BD1EC6A-5A5A-4618-ADCE-0F01AFD45545Q27341873-ADE52F97-6615-477F-8C6D-F799E92BC092Q28067128-979B2E7A-89EE-4C88-9BF5-471167F30218Q28087109-929D75D6-AD5F-4EED-B949-50734E05131AQ30409016-EE4AEAEE-215D-4778-92EB-8D2BAE31D9BBQ33589724-2E1F0E2D-6695-463C-933D-EE27663354FBQ33721705-79AFB1DB-12A5-4051-BC58-63D7C9541F6CQ33984012-C3A181E3-3F1F-4FF8-84BA-1D1A02741D68Q34278784-6C1D2DF5-1EF4-43FF-AA5E-7296C070972AQ34995740-1B56A2B5-E049-428A-9428-FEF3FEE0C69DQ35026193-16B43698-660F-4CF4-9E88-DB37CBD3ED5EQ35137541-2EEAE819-1344-42E2-A91F-D68E55823269Q35142870-4242732A-FEF3-4017-942A-EE036E1525BBQ35489060-949F1D9B-99E9-4903-9AEE-675CDDA3D363Q35631361-567AE18E-648B-46FF-8553-70B16071F16EQ35764897-C3F2DC47-699B-40B7-A87D-D5DB8C2D6E19Q35926637-7DF2A83D-61C6-4F64-BB81-17857F89DB49Q36353636-5056897C-ED5F-4B90-B434-DBA6D9808932Q36437128-998AC864-4687-4C80-B1BA-765076F96A3DQ36518152-D9B084E7-6E6D-450E-9568-E4C232ECEA56Q36650575-0DE4B86E-4E74-41AD-A21D-DFB6F32D54BFQ36723709-60C5DFF9-B65C-4188-B7B9-73005F679064Q36993177-2D40032A-288A-47AF-B05C-204815957AB0Q37043226-EEB252B9-C948-4022-AB10-9D4772CFE31EQ37113004-C3FCBE20-B364-4187-8D07-9221193CFAB0Q37183467-14E91CC0-D2AB-4094-A62A-941779CC88E4Q37339307-C1AAA9B3-C5A8-4A24-9014-F3A65FA73FB4Q37495794-37169A4A-60FC-4356-A5F8-0DCB26DAE3C7Q37496128-AAD5A49A-FAAF-4E1B-AEA8-399DE4E61132Q37590158-86183504-591F-4A98-AE99-04517067EE2BQ37723799-64BC5750-0308-43DF-9ED2-D6FA10B0EC5AQ37868371-F16FE5A7-4C3D-408F-BA2D-F1C9AC6BC70AQ37963121-E51F37C9-1A46-4750-996F-6B82AF1C2A7AQ37975121-AB624959-9EE8-40BA-9B82-2AF4F61EDC9EQ37989142-6C33C568-39F9-457F-B854-E199EFFAAAB6Q38056112-D879BEB8-D90F-45E2-95C9-53FA41D93F7EQ38083613-2FD03DFF-F1E3-4A98-A3A0-0CC3CC3F5584Q38095871-FA79551E-F3AF-4990-B918-01A74DE7923AQ38188453-B2FC268C-4921-4A3B-8BB4-919F39CC4A17Q38234313-6C44A532-C20B-42AC-A2F9-9A6081BCBDFB
P2860
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Upstream therapies for managem ...... s. Part I: primary prevention.
@en
Upstream therapies for managem ...... s. Part I: primary prevention.
@nl
type
label
Upstream therapies for managem ...... s. Part I: primary prevention.
@en
Upstream therapies for managem ...... s. Part I: primary prevention.
@nl
prefLabel
Upstream therapies for managem ...... s. Part I: primary prevention.
@en
Upstream therapies for managem ...... s. Part I: primary prevention.
@nl
P2093
P2860
P356
P1433
P1476
Upstream therapies for managem ...... es. Part I: primary prevention
@en
P2093
A John Camm
Antonios Kourliouros
Irene Savelieva
P2860
P304
P356
10.1093/EUROPACE/EUR002
P577
2011-03-01T00:00:00Z